AbbVie Inc. and OSE Immunotherapeutics SA have announced a strategic partnership to develop OSE-230, a monoclonal antibody in the pre-clinical development stage and designed to treat chronic and severe inflammation. OSE-230 is a first-in-class antibody that activates ChemR23, a G-protein-coupled receptor (GPCR), which could offer a novel approach to resolving chronic inflammation by modulating macrophages and neutrophils.
Jonathon Sedgwick, Ph.D., Senior Vice President at AbbVie, highlighted the collaboration as a testament to AbbVie’s dedication to expanding its immunology portfolio and improving care for patients with inflammatory diseases. Nicolas Poirier, CEO of OSE Immunotherapeutics, expressed satisfaction with partnering with AbbVie and recognized the milestone as an acknowledgment of the company’s innovative research and development efforts.
Under the partnership terms, AbbVie will receive an exclusive global license to develop, manufacture, and commercialize OSE-230, with OSE Immunotherapeutics receiving a $48 million upfront payment and up to an additional $665 million in potential clinical development, regulatory, and commercial milestones, as well as tiered royalties on global net sales of OSE-230.
The agreement is contingent upon customary closing conditions, including the waiting period stipulated by the Hart-Scott-Rodino Antitrust Improvements Act. This collaboration signifies a substantial advancement in addressing chronic inflammation through innovative therapeutic development.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
